Roquefort Therapeutics (LSE: ROQ, QTCQB: ROQAF) (Roquefort) is an LSE main-market-listed BioTech company exploring the high-value and high-growth oncology market. We at Colitco secured an exclusive interview with Ajan Reginald, CEO of Roquefort Therapeutics. Q: Ajan Reginald, thank you for agreeing to give Colitco an exclusive. Before we get into Roquefort Therapeutics and your company’s …
Roquefort Therapeutics PLC (LSE: ROQ, OTCQB: ROQAF), a cancer-focused biotechnology company, has made a significant announcement recently. The Company has signed an exclusive licensing and royalty agreement with Randox Laboratories Ltd., a global leader in medical diagnostics. The agreement (“Randox Licence Agreement”) pertains to Roquefort’s Midkine antibody portfolio and is limited to medical diagnostics. As …
Roquefort Therapeutics (LSE: ROQ, OTCQB: ROQAF) (“Roquefort” or the “Company”) announces that two of its Midkine (MDK) antibody programs, ROQ-A1 and ROQ-A2, demonstrate in-vivo safety in the pre-clinical development programs. The pre-clinical programs were carried out by leading cancer research groups. ROQ-A1 and ROQ-A2 are two patented antibody medicines designed by Roquefort to target metastatic breast …
Roquefort Therapeutics Reports In-Vivo Safety for Midkine Oncology Antibodies Read More »
Roquefort Therapeutics PLC (LSE: ROQ) (Roquefort or the “Company”) is a public company listed on the Main Market of the London stock exchange. Roquefort is a biotechnology company developing innovative cancer medicines in the high growth oncology market. Led by CEO Ajan Reginald, Roquefort has portfolio of four pre-clinical anti-cancer drugs and 46 registered patents. …
Roquefort Therapeutics and CEO Ajan Reginald: An Inspiring Story Read More »
